Bringing together ANTIBODY ENGINEERING & TIDES of Innovation: The Pep & Oligo Summit, the ANTIBODY & TIDES SUMMIT 2025 is where antibody power meets TIDES precision.
Launching in September:
IMAPAC's answer to the increasing demand for more effective biologic therapies.
Get ready! IMAPAC is heading to Amsterdam for the inaugural ANTIBODY & TIDES 2025 summit.
As the demand for more effective and diverse biologic therapies increases, TIDES of Innovation and the Antibody Engineering summit will address the key innovations driving the industry forward. From antibody discovery and engineering to biomanufacturing and emerging modalities, this event will provide a platform to discuss both the scientific advancements and industry challenges shaping the future of biotherapeutics
The biologics industry faces rising complexity in antibody development, necessitating smarter manufacturing and optimised regulatory compliance. With bioterapeutics growing more sophisticated, industry leaders are looking for solutions to scale production, reduce costs, and meet heightened regulatory demands without compromising quality.
These challenges are compounded by the evolving landscape of biologics, where the focus is shifting toward more personalised and potent treatments. At the same time, market competition is intensifying, and the push for cost-effective manufacturing processes continues to gain urgency
Thought leaders, industry influencers, and research specialists from biopharma, biotech, and CDMOs, will come together for these co-located events to explore critical advancements across the entire biologics lifecycle. From discovery and engineering through to biomanufacturing and commercialisation, this summit will provide a comprehensive view of the state-of-the-art innovations driving the future of biologic therapies.
Key Themes & Topics
At the heart of the first ANTIBODY & TIDES SUMMIT, the programme is set to cover the full spectrum of antibody and biologics innovation:
ANTIBODY DISCOVERY & ENGINEERING:
Covering cutting-edge methods like phage display and single-cell sequencing for antibody identification, with AI improving stability and binding.
Explore bispecific antibodies and Fc-engineering to enhance efficacy and half-life, exemplified by AstraZeneca’s T-cell engager therapies.
BIOMANUFACURING & SCALE UP:
Addressing scaling up biologic production, with a focus on optimising processes, increasing yields, and ensuring regulatory compliance.
AI and continuous manufacturing, including the FDA’s PAT framework, will be discussed, with Lonza’s modular systems as a key example.
EMERGING MODALITIES:
Exploring new biologic therapies like bispecific antibodies, ADCs, engineered cytokines, and immune modulators, this theme highlights innovations in targeting precision and therapeutic potency, including Roche’s Mosunetuzumab for relapsed lymphoma.
REGULATORY CONSIDERATIONS:
Navigating regulatory pathways for biologics, including the FDA’s Breakthrough Therapy designation and EMA’s PRIME programme, with a focus on CMC compliance, stability studies, and recent monoclonal antibody approvals in the EU.
COMMERCIALISATION STRATEGIES:
Focusing on strategies for market entry, this theme covers partnerships, pricing, and biosimilar competition, using Amgen’s portfolio of biologics and biosimilars to demonstrate market leadership.
At the heart of the first ANTIBODY & TIDES SUMMIT, the programme is set to cover the full spectrum of antibody and biologics innovation:
ANTIBODY DISCOVERY & ENGINEERING:
Covering cutting-edge methods like phage display and single-cell sequencing for antibody identification, with AI improving stability and binding.
Explore bispecific antibodies and Fc-engineering to enhance efficacy and half-life, exemplified by AstraZeneca’s T-cell engager therapies.
BIOMANUFACURING & SCALE UP:
Addressing scaling up biologic production, with a focus on optimising processes, increasing yields, and ensuring regulatory compliance.
AI and continuous manufacturing, including the FDA’s PAT framework, will be discussed, with Lonza’s modular systems as a key example.
EMERGING MODALITIES:
Exploring new biologic therapies like bispecific antibodies, ADCs, engineered cytokines, and immune modulators, this theme highlights innovations in targeting precision and therapeutic potency, including Roche’s Mosunetuzumab for relapsed lymphoma.
REGULATORY CONSIDERATIONS:
Navigating regulatory pathways for biologics, including the FDA’s Breakthrough Therapy designation and EMA’s PRIME programme, with a focus on CMC compliance, stability studies, and recent monoclonal antibody approvals in the EU.
COMMERCIALISATION STRATEGIES:
Focusing on strategies for market entry, this theme covers partnerships, pricing, and biosimilar competition, using Amgen’s portfolio of biologics and biosimilars to demonstrate market leadership.
What to Expect at the ANTIBODY & TIDES 2025 Summit:
Attendees from 100+ Organisations participating in discussion on the development and significance of TIDE therapeutics and antibody engineering.
60+ Expert Speakers across both programmes, presenting on critical advancements in biologic therapies.
Over 16 hours of dedicated face-to-face networking, including 1:1 meetings and interactive sessions
